OREANDA-NEWS. Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the appointment of noted scientists Bonnie L. Bassler, Ph.D., and Huda Y. Zoghbi, M.D., to the company's Board of Directors.

"Regeneron continues to maintain a Board of Directors primarily comprised of accomplished scientists, who provide critical input to the company's scientific, technological and clinical strategy," said P. Roy Vagelos, M.D., Chairman, Regeneron Board of Directors. "We are thrilled to welcome Bonnie and Huda to the Board, as both bring incredible passion and a track record of scientific achievement. Bonnie's lifelong work as a molecular biologist and Huda's expertise in genetics and medical research strengthen Regeneron's scientific approach. Bonnie and Huda recognize that deep understanding of the biologic and genetic underpinnings of disease is essential to rapidly advance an innovative pipeline of potential new medicines for patients with serious diseases."

About Dr. Bassler

Dr. Bassler is the Chair of the Department of Molecular Biology and the Squibb Professor in Molecular Biology at Princeton University. She has been a Howard Hughes Medical Institute Investigator since 2005. Dr. Bassler's research focuses on bacterial cell-to-cell communication and how communication controls collective behaviors including pathogenicity. She has previously served on the Boards for the American Association for the Advancement of Science, the National Science Foundation and the American Academy of Microbiology. Dr. Bassler also served as the President of the American Society for Microbiology. She was elected to the National Academy of Sciences in 2006, the American Academy of Arts and Sciences in 2007, and the Royal Society and the American Philosophical Society in 2012. Dr. Bassler has received many scientific honors including a MacArthur Foundation Fellowship, the Lounsbery Award and the Shaw Prize for Life Science and Medicine.

"I have known the Regeneron leadership team for many years, and I am proud to be joining them on the Board," said Dr. Bassler. "Regeneron is committed to basic biology research, and I look forward to supporting its important work to unlock key questions of human disease."

Dr. Bassler received her B.Sc. from the University of California, Davis, and her Ph.D. in Biochemistry from the Johns Hopkins University. She served as a Postdoctoral Fellow and Research Scientist at the Agouron Institute in La Jolla, California, before becoming a faculty member at Princeton University.

About Dr. Zoghbi

Dr. Zoghbi is best known for her important work in neurology and the genetics of neurological diseases. She has been a professor in the departments of Pediatrics, Molecular and Human Genetics, and Neurology and Neuroscience at Baylor College of Medicine since 1994, the director of the Jan and Dan Duncan Neurological Research Institute at Texas Children's Hospital since 2010, and an investigator of the Howard Hughes Medical Institute since 1996. Dr. Zoghbi has been elected to the National Academy of Sciences, the Institute of Medicine and the American Association for the Advancement of Science. She has been awarded numerous recognitions for her work including the Pearl Meister Greengard Prize, the March of Dimes Prize in Developmental Biology and the Vanderbilt Prize in Biomedical Science.

Dr. Zoghbi earned her B.Sc. from the American University of Beirut, received her M.D. from Meharry Medical College in Nashville, Tennessee, and completed her pediatrics residency and a joint residency in neurology and pediatric neurology at Baylor College of Medicine, where she then pursued postdoctoral research training in molecular genetics.

About Regeneron Pharmaceuticals, Inc.
Regeneron (NASDAQ: REGN) is a leading science-based biopharmaceutical company based in Tarrytown, New York that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. Regeneron commercializes medicines for eye diseases, high LDL cholesterol and a rare inflammatory condition and has product candidates in development in other areas of high unmet medical need, including rheumatoid arthritis, atopic dermatitis, asthma, pain, cancer and infectious diseases.